1989
The FDA approved Oculinum's botulinum toxin for strabismus on December 29, 1989, through the orphan drug pathway.
“On December 29th, 1989, through an orphan drug approval pathway, Oculinum gets official FDA approval to manufacture and sell botulinum toxin for the treatment of strabismus.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:16:18
1990s
Dan Carpenter says many countries, especially in Europe, long waited for the FDA to mandate drug tests before approving drugs themselves.
“a number of other countries, especially in Europe, but around the world, basically waited for the FDA to mandate tests on a drug.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:05:30
2000s
Bancel says an FDA warning letter on Eli Lilly's injectable insulin manufacturing site held up Lilly's planned biologic launches, because those products were to be made in the same plant.
“because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well.”
Stéphane Bancel · Ep11: Stephane Bancel, 0:18:06
2001
In July 2001 an FDA advisory committee voted 8-1 against approving Symlin for type 1 diabetes and 6-3 against for type 2.
“The panel votes 8-1 against approving the drug for type 1 diabetes. They vote 6-3 against type 2.”
Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:38:01
2002
Botox Cosmetic received FDA approval in 2002, years after dermatologists began using Botox off-label for wrinkles.
“you may be surprised to learn that Botox Cosmetic doesn't actually get FDA approval until 2002.”
Matthew Pech · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 1:44:10
2004
Avastin, the first approved drug of this angiogenesis-blocking type, was approved by the FDA in 2004, 28 years after the 1976 work.
“in 2004, 28 years after we started, the first one of those, Avastin, got approved by the FDA.”
Bob Langer · #105 – Robert Langer: Edison of Medicine, 0:18:25
2004
Gottlieb says the emergency use authorization pathway originated in Project BioShield, post-9/11 legislation for rapid authorization of countermeasures to bioterrorist attacks.
“The emergency use authorization, which was originally derived in Project BioShield, it was sort of post-9 -11 legislation on how to create a pathway for the rapid regulatory authorization”
Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:08:38
2005
The FDA approved Symlin (pramlintide) on March 16, 2005, as the first new class of type 1 diabetes medicine since insulin.
“It's approved, and it's now the first new class of medicines approved for type 1 diabetes since the discovery of insulin itself 80 years earlier.”
Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:46:52
2010
Michael Abramoff went to an FDA meeting in 2010 and told the agency he wanted a computer to make a diagnosis.
“I ultimately ended up going to FDA in 2010 at a meeting, said, I want a computer to make a diagnosis.”
Michael Abramoff · No Doctor Needed? Dr. Michael Abramoff on the Potential of Autonomous AI, 0:16:07
2011
According to Alex Kesin, Allergan spent about $60 million around 2011 to get a new potency assay accepted by the FDA to replace the mouse lethality test.
“I remember reading that in 2011, they spent like $60 million to get a new assay for the FDA.”
Alex Kesin · Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise, 2:59:17
2014
On March 12, 2014, the FDA placed a full clinical hold on all imetelstat trials over liver toxicity, and Geron's stock fell more than 60 percent that day.
“On March 12, 2014, the FDA places a full clinical hold on all Amelstat trials.”
Matthew Pech · Episode #2: Geron, 1:42:48
2016
George Yancopoulos said the FDA approved 22 medicines in 2016, of which only eight were first in class.
“Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class.”
George Yancopoulos · Ep3: George Yancopoulos, 0:09:04
2017-2018
Gottlieb says the 2017-2018 flu vaccine was only about 25 percent protective against the predominant influenza strain that season.
“It was only 25 % protective against the predominant strain of influenza in that season.”
Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:48:24
2018
In 2018 the FDA authorized Digital Diagnostics' IDx-DR, described as the first FDA authorization of an autonomous AI that works without physician input.
“Back in 2018, the FDA issued authorization for your company's device, which I understand was the first FDA authorization for an autonomous AI without physician input.”
Arjun Manrai · No Doctor Needed? Dr. Michael Abramoff on the Potential of Autonomous AI, 0:11:49
2020
Andrew von Eschenbach says the FDA approved clinical trials using the body's immune system, including natural killer cells, against the coronavirus.
“FDA has approved clinical trials to use our own body's immune system, including using natural killer cells that are already in our body.”
Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:08:11
2020
Gottlieb says the FDA required the full trial data set and two months of follow-up on half the patients before authorizing COVID-19 vaccines.
“the FDA moved towards a posture where they required the full data set and two months of follow-up on 50 % of the patients in the clinical trial before they would authorize the vaccines.”
Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:10:15
2021
The FDA authorized Pfizer's Covid booster for people six months past their primary series who are 65 or older or at high risk of severe Covid.
“The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID”
Meg Terrell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:04:54
2021
Acting FDA Commissioner Janet Woodcock said the high-exposure group for Pfizer boosters includes teachers, daycare workers, grocery workers, and people in prisons and homeless shelters.
“Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.”
Meg Terrell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:04:54
2021
Meg Terrell described the booster approval path as FDA advisers, then the FDA, then the CDC's advisory committee, then CDC director sign-off.
“the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it”
Meg Terrell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:04:33
2021
The Biden administration wanted boosters for everyone, but the FDA's advisory committee VRPAC said the evidence did not support that.
“the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that.”
Helen Branswell · Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout, 0:14:45
2021
Amy Abernethy says the FDA issued three core guidances on real-world data at the end of 2021, informed by the collaborative process she described.
“That then informed the guidance that came out from FDA at the end of 2021. There were three core guidances around robot data, all informed by that process.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:11:30
2021
Amy Abernethy says the FDA published an action plan for AI-based medical software around January 2021.
“And I think it was like around January 2021, put out an action plan to specify, here are the details of what we think good's going to look like in this space.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:11
2021
Amy Abernethy says the FDA's AI action plan called for good software design and an easy way to understand an AI product's output.
“We need, you know, good software design. We need to make sure that there is an easy way to understand the output of an AI-based product”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:11
2021
Amy Abernethy says the FDA's AI action plan also called for validation testing and performance monitoring over time.
“we need appropriate validation testing and we need some mechanism for performance monitoring across time.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:11
2022
Linda Ritchie of the FDA was the government co-lead of the strategic plan task group.
“And then the government co-lead was FDA, Linda Ritchie.”
Greg Garcia · Episode #68. The Health Industry Cybersecurity Strategic Plan Unveiled, with Greg Garcia, Executive Director of the Health Sector Coordinating Council, 0:15:09
2023
A CRISPR-based sickle cell therapy was the first CRISPR therapeutic up for FDA approval at the time of recording.
“Geneticists made use of that function to develop a cure for sickle cell disease, which is currently the first CRISPR-based therapeutic up for approval by the FDA.”
Bapu Jena · 72. What’s Stopping Us From Curing Rare Diseases?, 0:24:15
2023
Robert Califf marked one year as commissioner of the U.S. Food and Drug Administration around March 2023.
“Dr. Robert Califf recently marked his one-year anniversary as commissioner of the U.S. Food and Drug Administration.”
Host · 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity, 0:06:53
2023
Robert Califf said US infant formula in-stock rates had returned to pre-recall levels, though some rural areas still lagged.
“First of all, our in-stock rates are back to where they were before the recall.”
Robert Califf · 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity, 0:22:16
2024
On March 14, 2024, the FDA's Oncology Drugs Advisory Committee voted 12 to 2 that imetelstat's benefits outweigh its risks.
“On March 14, 2024, FDA's Oncology Drugs Advisory Committee votes 12 to 2 that the benefits of the metal stat outweigh its risk.”
Matthew Pech · Episode #2: Geron, 1:49:53
2024
On June 6, 2024, the FDA approved imetelstat for low-risk myelodysplastic syndromes, making it the first approved telomerase inhibitor.
“And on June 6, 2024, the FDA ultimately approves metal stat, now called Rotello, for its use in low-risk MDS.”
Matthew Pech · Episode #2: Geron, 1:50:28
Undated
Andrew von Eschenbach says that while he led the FDA, much production of drug ingredients, excipients and gelatin capsules took place outside the United States.
“the production of, for example, active pharmaceutical ingredients and excipients, even the gelatin that you find your medicines encapsulated in, and many other things were occurring and being developed outside the United States.”
Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:13:54
Undated
Under Andrew von Eschenbach, the FDA created its 'Beyond Our Borders' program and placed personnel and offices in China, India, Europe, Central America and later the Middle East.
“we created FDA Beyond Our Borders and actually put FDA personnel and offices in China, in India, in Europe, in Central America, and eventually in the Middle East.”
Andrew von Eschenbach · Ep. 8: Legacy, with former FDA Commissioner Andrew von Eschenbach, 0:14:35
Undated
Langer says engineered skin has been approved by the FDA.
“skin's already been made and approved by the FDA. There are advanced clinical trials, like what are called phase three trials”
Bob Langer · #105 – Robert Langer: Edison of Medicine, 0:31:11
Undated
Scott Gottlieb served as the 23rd commissioner of the U.S. Food and Drug Administration.
“Dr. Scott Gottlieb, physician and former head of the U.S. Food and Drug Administration. He was the 23rd commissioner.”
Speaker 5 · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:00:00
Undated
Gottlieb recalls that the largest vaccine trial he knew of at the FDA was a rotavirus vaccine trial of around 60,000 patients.
“The largest vaccine trial I remember from being at FDA was the rotavirus vaccine. I think it was around 60 ,000 patients.”
Scott Gottlieb · Uncontrolled Spread: Science, Policy, Institutions, Infrastructure, 0:16:35
Undated
Viz.ai has an FDA-approved algorithm for detecting stroke in the emergency room.
“One example is a company called VizAI that has an FDA-approved algorithm for detecting stroke in the emergency room.”
Gaurav Singal · 72. What’s Stopping Us From Curing Rare Diseases?, 0:07:02
Undated
The CRISPR treatment that cured Jimmy Olaher's sickle cell disease is the first CRISPR-based therapeutic up for approval by the U.S. FDA.
“The treatment that cured Jimmy's sickle cell disease is now the first CRISPR-based therapeutic up for approval by the FDA, meaning it could hit the market as early as this year.”
Bapu Jena · 73. Who Pays for Multimillion-Dollar Miracle Cures?, 0:06:00
Undated
Andrew Lowe says FDA approval of a new drug generally takes about 5 to 15 years, depending on the disease.
“the FDA approval process generally takes on the order of 5 to 15 years, depending on the nature of the disease.”
Andrew Lowe · 73. Who Pays for Multimillion-Dollar Miracle Cures?, 0:12:06
Undated
Robert Califf said the current system filters out about 85% of ineffective candidates in phase one, two and early phase three trials.
“We winnow out 85 % of things that don't work in phase one, two, and early phase three trials.”
Robert Califf · 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity, 0:14:13
Undated
Robert Califf said FDA advisory committees exist to gather expert thinking rather than to take a vote, since the FDA makes the decisions.
“Purpose of the advisory committee is not to take a vote. Purpose of the advisory committee is to get the thinking of experts about the problem at hand.”
Robert Califf · 249: Robert Califf on how drugs get approved, plus the nascent revolution in obesity, 0:15:55
Undated
Michael Abramoff says his company showed there was no racial bias in its AI, which the FDA examined.
“in our case, we proved that there was no racial bias in AI.”
Michael Abramoff · No Doctor Needed? Dr. Michael Abramoff on the Potential of Autonomous AI, 0:40:48
Undated
Michael Abramoff says his paper with the FDA divides explainability into validability, explainability and transparency.
“three very different types of explainability we call them validability explainability and transparency in the paper”
Michael Abramoff · No Doctor Needed? Dr. Michael Abramoff on the Potential of Autonomous AI, 0:55:36
Undated
Amy Abernethy says the Evidence Accelerator brought the FDA and innovators together so regulators could say which evidence they trusted and what they wanted to know more about.
“We called this the evidence accelerator. And regulators and others could say, I trust this, I don't trust that, here's what I want to know more about.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:07:13
Undated
Amy Abernethy says AI-based products can be regulated under the FDA's traditional device framework, such as diagnostics or software as a medical device.
“We can regulate them according to the traditional device framework, whether that's a diagnostic or a software as a medical device.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:18:08
Undated
Amy Abernethy says that, as far as she knew, the FDA's AI action plan had not been turned into a new rule set.
“that actually hasn't translated to a new rule set, as far as I know, beyond what we've previously had.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:19:45
Undated
Amy Abernethy says companies traditionally submit clinical trial results to the FDA as hundreds of pages of reports and then wait for questions.
“you ultimately package up the clinical trial, write hundreds of pages of reports, and ultimately ship that over the FDA and wait for questions to come back.”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:20:47
Undated
Amy Abernethy says that while at the FDA she worked on infrastructure so companies could push data directly to the agency instead of submitting lengthy reports.
“we were building the pipes at FDA to be ready for a landscape where really all you do is push your data across over FDA and FDA is ready to receive”
Amy Abernethy · AI, Innovation, and Regulatory Insights with Amy Abernethy, 0:21:23
Undated
The FDA has granted software-as-a-medical-device approval to Mayo's algorithm that analyzes single-lead Apple Watch ECG data, per Halamka.
“and FDA has now given it full software as a medical device approval to be used as part of diagnosis for patients.”
John Halamka · Upgrading Your Health: Navigating AI's Future In Healthcare with John Halamka of Mayo Clinic Platform, 0:24:38
Undated
Andrew Huberman says the FDA decided NMN could no longer be sold as a supplement because a clinical trial had been started on it.
“the FDA decided that it should not be sold over the counter, um, anymore because there was a clinical trial initiated on NMN”
Andrew Huberman · Supplements for Longevity & Their Efficacy | Dr. Peter Attia, 1:36:15
Undated
Farrugia says a company's epilepsy algorithm showed weaker performance in one population group when tested on Mayo's Validate, was corrected, and then went on to gain FDA approval.
“a company that had an epilepsy algorithm performed really great but there was one section of the population where it didn't do as well and they were able to go back change that and get fda”
Gianrico Farrugia · Healthcare at an inflection point - Mayo Clinic CEO Dr. Gianrico Farrugia, 0:16:31
Undated
Teresa Carlson argues that the FDA should lead healthcare AI policy rather than creating broad new regulation.
“The FDA has been doing their job a long time. Let's let them actually work toward what the right policy is for their environment for healthcare.”
Teresa Carlson · AI in Healthcare: Reality, ROI, and Patient Outcomes | CXOTalk #874, 0:11:05
Undated
Brice Challamel says the FDA published draft guidance on AI usage in January.
“The FDA has published a draft guidance on AI usage for various use cases in January.”
Brice Challamel · #249 Brice Challamel: How Moderna is Using AI to Disrupt Modern Healthcare, 0:29:57
Undated
The FDA worked with Moderna on approval of the COVID vaccine, which Brice Challamel describes as the first mRNA product to reach the American market.
“They were an amazing partner to Moderna in the approval process of the very first mRNA product ever to go to market in America, which was the COVID vaccine.”
Brice Challamel · #249 Brice Challamel: How Moderna is Using AI to Disrupt Modern Healthcare, 0:28:54
Undated
Dan Carpenter says the U.S. Food and Drug Administration requires drugmakers to prove effectiveness as well as safety and non-toxicity.
“The FDA wants you to prove not simply that it's safe and non-toxic, but also that it's effective.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:03:17
Undated
Dan Carpenter describes the FDA as a veto player that controls which drugs can enter the U.S. market.
“it stands as what I would call the veto player over R &D to the marketplace. The FDA basically has sort of this control over entry to the marketplace.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:04:01
Undated
According to Dan Carpenter, phase two drug trials focus mainly on safety with some attention to efficacy, in people who have the disease.
“Then there's a set of phase two trials where they look more at safety and a little bit at efficacy.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:04:01
Undated
Dan Carpenter says phase three trials are large randomized clinical trials assessing efficacy and are very expensive for companies.
“phase three involves a much more direct and large-scale attack if you will or assessment of efficacy and that's where you get the sort of large randomized clinical trials that are very expensive”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:04:33
Undated
Dan Carpenter explains that surrogate endpoints, such as tumor measurements, are used for cancer drugs because waiting to see who survives longer can delay decisions.
“the idea is that a cancer drug, we really want to know whether that drug saves lives. But if we wait to see whose lives are saved or prolonged by that drug, we might miss the opportunity”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:08:02
Undated
Dan Carpenter says FDA approval covers a drug together with its dosage frequency and method of administration, which trials help establish.
“it's not simply a drug that's approved. It's a drug and a frequency of administration. It's a method of administration.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:12:16
Undated
Dan Carpenter says clinical trials are run by companies, not by the FDA, contrary to a common belief.
“Well, some people tend to think that the FDA performs them. It's companies that do it.”
Dan Carpenter · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:13:50
Undated
Timo Minssen says the FDA had authorized more than 1,000 AI and machine-learning-enabled medical devices as of its latest update he knew of.
“the FDA has authorized more than 1 ,000 AI machine learning enabled medical devices.”
Timo Minssen · AI Testing and Evaluation: Learnings from pharmaceuticals and medical devices, 0:17:02
Undated
Daphne Koller says the U.S. Food and Drug Administration has embraced AI much more than in previous years.
“I mean, even the FDA has moved to embrace AI much more now than it's had in the past few years.”
Daphne Koller · The Machine Learns Medicine: Daphne Koller’s Vision for AI in Biotech, 0:34:34
Undated
Tessier-Lavigne cites about 13 years on average from target to FDA approval, with only about one in ten clinical drugs succeeding.
“it's 13 years on average to go from having a target, making the drug and getting it through clinical trials to FDA approval”
Marc Tessier-Lavigne · Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI, 1:09:14
Undated
Sam Ransbotham says Philips recently received FDA clearance for SmartHeart, an automated cardiac MR planning tool.
“I think Philips just got FDA clearance for Smart Heart, which is a automated cardiac MR planning tool.”
Sam Ransbotham · AI for Interoperability in Health Care: Philips’s Carla Goulart Peron, 0:09:52
Undated
An IND, or Investigational New Drug Application, is the submission sent to the U.S. FDA explaining a drug before clinical trials can begin.
“IND is Investigational New Drug Application. And in the United States, that is the submission that you have to send to FDA explaining your drug to them effectively”
Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:11:38
Undated
Brandon Rice says NDA paperwork was once shipped to the FDA in a semi-truck, and that electronic PDF submission kept the same volume of paper.
“it used to be that you would fill the back of a semi-truck with all of the paperwork for your NDA, that market approval application I mentioned, and you would literally ship it to FDA.”
Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:18:39
Undated
Brandon Rice contrasts regulation in many industries, which he likens to a fence with fines for stepping outside, with drug regulation, which he likens to a railroad.
“In many industries, it's a fence around what you're allowed to do. And if you step outside that fence, you get fined.”
Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:09:31
Undated
Brandon Rice says the U.S. FDA is interested in applying AI and already has its own initiatives for reviewing submissions.
“Today's FDA has an appetite for AI and is very interested in figuring out how to apply these technologies to their problems”
Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:17:11
Undated
Andy Beam says the FDA previously expressed willingness to accept computational models of antibody designs in place of animal models.
“the FDA previously said they would express willingness for computational models of antibody designs instead of animal models”
Andrew Beam · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:29:26
Undated
Brandon Rice says several Weave customers submitted AI-produced submissions to the FDA, had them approved, and now have those drugs in clinical trials.
“They submitted those to FDA, they've been approved and those drugs are now in clinic.”
Brandon Rice · Weave’s Brandon Rice on Rebuilding Drug Regulation with AI, 0:40:19
Undated
Bancel said he expects the treatment to be approved as a process-based biologics license application, as CAR-T therapies were, rather than as a fixed product.
“CAR-T was also approved in the same way as we believe this one will be, which is as a process BLA, not a product BLA.”
Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:28:11
Undated
Bancel said Moderna has five approved products, but its individualized cancer treatment has been handled with a process IND since it entered the clinic.
“Moderna has five product approved. So that's really product approval. On this one, the whole process since we started in the clinic, the IND was a process IND.”
Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:28:11
Undated
Daphne Koller says between 9 and 22 percent of diseases have any FDA-approved therapeutic.
“the fraction of diseases that have any FDA-approved therapeutic, even if it's addressing purely symptoms, depending on whose estimates you believe, it's somewhere between 9 % to 22%”
Daphne Koller · Ep213: Daphne Koller on The Moment in AI Drug Discovery, 0:05:36